78 related articles for article (PubMed ID: 16732049)
1. Treatment of hyperglycemia in a 7-year-old child diagnosed with neonatal diabetes.
Hathout E; Mace J; Bell GI; Njølstad PR
Diabetes Care; 2006 Jun; 29(6):1458. PubMed ID: 16732049
[No Abstract] [Full Text] [Related]
2. Transition from insulin to glyburide in a 4-month-old girl with neonatal diabetes mellitus caused by a mutation in KCNJ11.
Chan YM; Laffel LM
Pediatr Diabetes; 2007 Aug; 8(4):235-8. PubMed ID: 17659066
[TBL] [Abstract][Full Text] [Related]
3. Neonatal diabetes in a child positive for islet cell antibodies at onset and Kir6.2 activating mutation.
Gach A; Wyka K; Pietrzak I; Wegner O; Malecki MT; Mlynarski W
Diabetes Res Clin Pract; 2009 Nov; 86(2):e25-7. PubMed ID: 19692135
[TBL] [Abstract][Full Text] [Related]
4. [Diabetes in infants may be treated with sulfonylurea as a replacement for insulin].
Lauridsen MH; Boesgaard TW; Pedersen OB; Hansen T; Hertz B
Ugeskr Laeger; 2009 Jun; 171(23):1923-4. PubMed ID: 19500515
[TBL] [Abstract][Full Text] [Related]
5. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
Bremer AA; Ranadive S; Lustig RH
Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
[TBL] [Abstract][Full Text] [Related]
6. Sulphonylurea treatment does not improve psychomotor development in children with KCNJ11 mutations causing permanent neonatal diabetes mellitus accompanied by developmental delay and epilepsy (DEND syndrome).
Sumnik Z; Kolouskova S; Wales JK; Komarek V; Cinek O
Diabet Med; 2007 Oct; 24(10):1176-8. PubMed ID: 17888143
[No Abstract] [Full Text] [Related]
7. Sulfonylurea-responsive diabetes in childhood.
Landau Z; Wainstein J; Hanukoglu A; Tuval M; Lavie J; Glaser B
J Pediatr; 2007 May; 150(5):553-5. PubMed ID: 17452235
[TBL] [Abstract][Full Text] [Related]
8. Islet-specific antibody seroconversion in patients with long duration of permanent neonatal diabetes caused by mutations in the KCNJ11 gene.
Gach A; Wyka K; Malecki MT; Noczynska A; Skupien J; Nazim J; Szalecki M; Bodalski J; Sieradzki J; Mlynarski W
Diabetes Care; 2007 Aug; 30(8):2080-2. PubMed ID: 17475937
[No Abstract] [Full Text] [Related]
9. [Glycemic index of meals and postprandial glycemia in patients with permanent neonatal diabetes due to Kir6.2 gene mutations].
Klupa T; Małecki M; Skupień J; Szalecki M; Jałowiec I; Surdej B; Myśliwiec M; Sieradzki J
Przegl Lek; 2007; 64(6):398-400. PubMed ID: 18159846
[TBL] [Abstract][Full Text] [Related]
10. Early glibenclamide treatment in a clinical newborn with KCNJ11 gene mutation.
Däublin G; Lorenz-Depiereux B; Strom TM; Blankenstein O; Raile K
Diabetes Care; 2007 Oct; 30(10):e104. PubMed ID: 17901525
[No Abstract] [Full Text] [Related]
11. Sulfonylurea use during entire pregnancy in diabetes because of KCNJ11 mutation: a report of two cases.
Gaal Z; Klupa T; Kantor I; Mlynarski W; Albert L; Tolloczko J; Balogh I; Czajkowski K; Malecki MT
Diabetes Care; 2012 Jun; 35(6):e40. PubMed ID: 22619292
[No Abstract] [Full Text] [Related]
12. [From injections to pills--neonatally diagnosed diabetes of mother and baby].
Kaunisto K; Ojaniemi M; Juuti AK; Huopio H; Laakso M; Veijola R
Duodecim; 2011; 127(6):559-62. PubMed ID: 21528521
[TBL] [Abstract][Full Text] [Related]
13. Permanent neonatal diabetes due to KCNJ11 gene mutation.
Letha S; Mammen D; Valamparampil JJ
Indian J Pediatr; 2007 Oct; 74(10):947-9. PubMed ID: 17978456
[TBL] [Abstract][Full Text] [Related]
14. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
Flechtner I; de Lonlay P; Polak M
Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510
[TBL] [Abstract][Full Text] [Related]
15. Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity.
Malecki MT; Skupien J; Klupa T; Wanic K; Mlynarski W; Gach A; Solecka I; Sieradzki J
Diabetes Care; 2007 Jan; 30(1):147-9. PubMed ID: 17192350
[No Abstract] [Full Text] [Related]
16. Infantile spasms as an epileptic feature of DEND syndrome associated with an activating mutation in the potassium adenosine triphosphate (ATP) channel, Kir6.2.
Bahi-Buisson N; Eisermann M; Nivot S; Bellanné-Chantelot C; Dulac O; Bach N; Plouin P; Chiron C; de Lonlay P
J Child Neurol; 2007 Sep; 22(9):1147-50. PubMed ID: 17890419
[TBL] [Abstract][Full Text] [Related]
17. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation.
Codner E; Flanagan S; Ellard S; García H; Hattersley AT
Diabetes Care; 2005 Mar; 28(3):758-9. PubMed ID: 15735229
[No Abstract] [Full Text] [Related]
18. Sulfonylurea treatment in young children with neonatal diabetes: dealing with hyperglycemia, hypoglycemia, and sick days.
Codner E; Flanagan SE; Ugarte F; García H; Vidal T; Ellard S; Hattersley AT
Diabetes Care; 2007 May; 30(5):e28-9. PubMed ID: 17337505
[No Abstract] [Full Text] [Related]
19. Sulfonylrea treatment in permanent neonatal diabetes due to G53D mutation in the KCNJ11 gene: improvement in glycemic control and neurological function.
Gurgel LC; Crispim F; Noffs MH; Belzunces E; Rahal MA; Moisés RS
Diabetes Care; 2007 Nov; 30(11):e108. PubMed ID: 17965292
[No Abstract] [Full Text] [Related]
20. Permanent neonatal diabetes.
Bakri D; Gershoni-Baruch R; Shehadeh N
Isr Med Assoc J; 2004 May; 6(5):290-1. PubMed ID: 15151370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
